You are viewing the site in preview mode
Skip to main content
|
First author, year, and country
|
Study
|
Disease
|
No. (MSCs+/MSCs−)
|
Median/mean age (year) (MSCs+/MSCs−)
|
HSCs source (donor type)
|
HSCs HLA matching
|
MSCs source (donor type)
|
MSCs dose (106/kg)
|
Median follow-up time (month) (MSCs+/MSCs−)
|
|---|
|
Ning, 2008, China [24]
|
RCT
|
HM
|
25 (10/15)
|
38/37
|
BM, PB, BM+PB (RD)
|
ID
|
BM (RD)
|
0.34 (0.03–1.53)
|
36.6 (0.6–44.0)
|
|
Ghavamzad, 2010, Iran [27]
|
RCT
|
NMD
|
48 (25/23)
|
17/16
|
PB, BM (RD)
|
ID
|
NA (RD)
|
1.45–1.80
|
10 (1–28)
|
|
Liu, 2011, China [22]
|
RCT
|
HM
|
55 (27/28)
|
30/31.5
|
BM+PB (RD)
|
HID
|
BM (RD, TPD)
|
0.3–0.5
|
23.7 (0.7–33.5)
|
|
Wu, 2013b, China [28]
|
RCT
|
HM
|
20 (8/12)
|
9.8/8.5
|
UCB (URD)
|
MM
|
UCB (URD)
|
7.19 (2.44–10.12)
|
16.5 (11–27)/18.5 (12–31)
|
|
Mareika, 2016, Belarus [29]
|
RCT
|
HM
|
22 (10/12)
|
13 (5–24)
|
NA (NA)
|
NA
|
BM (NA)
|
1.56 ± 0.4
|
38 (5.7–59.4)
|
|
Xiang, 2017, China [13]
|
RCT
|
HM
|
64 (32/32)
|
5.5 ± 1.4/5.2 ± 1.2
|
PB (URD)
|
ID
|
UCB (URD)
|
1.0
|
24
|
|
Ball, 2007, Netherlands [16]
|
HCT
|
HM and NMD
|
61 (14/47)
|
8 (1–16)/7.1 (1–17)
|
PB (RD)
|
HID
|
BM (RD)
|
1.6 (1.0–3.3)
|
(3–28)/(32–110)
|
|
Gonzalo-Daganzo, 2009, Spain [30]
|
PCT
|
HM
|
55 (9/46)
|
32/35
|
UCB (URD)
|
MM
|
BM (URD)
|
1.2 (1.04–2.22)
|
7.4 (1–22)/24 (1–107)
|
|
MacMillan, 2009, USA [31]
|
HCT
|
HM
|
30 (7/23)
|
7.5 (0.2–16)
|
UCB (URD)
|
MM
|
BM (RD)
|
2.1 (0.9–5.0)
|
81.6
|
|
Baron, 2010, Belgium [32]
|
HCT
|
HM
|
36 (20/16)
|
58/55
|
PB (URD)
|
MM
|
BM (URD)
|
NA
|
18.7 (13.3–30.3)
|
|
Hou, 2010 China [33]
|
PCT
|
HM
|
35 (15/20)
|
32 (14–45)/28.5 (12–48)
|
NA (RD)
|
HID
|
BM (RD, 2; TPD, 13)
|
0.41 (0.22–0.52)
|
6
|
|
Bernardo, 2011, Italy [15]
|
HCT
|
HM
|
52 (13/39)
|
2/4
|
UCB (URD)
|
MM
|
BM (RD)
|
1.9 (1–3.9)
|
36 (28/42)
|
|
Lee, 2013, Korea [14]
|
HCT
|
HM
|
16 (7/9)
|
6.9/9.5
|
UCB (URD)
|
MM
|
UCB (URD)
|
1.0 in 4 pts, 5.0 in 3 pts
|
24
|
|
Wu, 2013a, China [34]
|
PCT
|
HM and NMD
|
14 (5/9)
|
8.8/7.8
|
UCB (URD)
|
MM
|
UCB (URD)
|
5.76 (3.12–8.21)
|
27 (24–31)
|
|
Xiao, 2013, China [35]
|
PCT
|
HM and NMD
|
15 (7/8)
|
30 (12–60)/35.5 (16–54)
|
PB (URD)
|
NA
|
UCB (URD)
|
NA
|
15
|
|
Wang, 2015, China [36]
|
PCT
|
NMD
|
14 (7/7)
|
28 (22–43)
|
PB (RD)
|
MM
|
UCB (URD)
|
Total, 30.0
|
14.5 (6–74)
|
|
Zhang, 2015, China [37]
|
HCT
|
HM
|
49 (22/27)
|
22.5 (3–48)/23 (3–43)
|
PB (URD)
|
MM
|
UCB (URD)
|
1.0
|
22 (1–98)
|
|
Kang, 2017, China [38]
|
HCT
|
HM
|
47 (34/13)
|
7 (1.5–13)
|
PB, BM (RD)
|
HID
|
UCB (URD)
|
1.0
|
20 (0.5–67)
|
|
Ghavamzad, 2017, Iran [39]
|
PCT
|
NMD
|
70 (41/29)
|
NA
|
NA (RD)
|
ID
|
NA (URD)
|
1.0–2.0
|
35.76/31.44
|
- RCT randomized controlled trial, PCT prospective controlled trial, HCT historical controlled trial, HM hematological malignancies, NMD non-malignant disorders, PB peripheral blood, BM bone marrow, UCB umbilical cord blood, RD related donor, URD unrelated donor, NA not available, pts patients, ID identical, HID haploidentical, MM mismatched
